Investigational new drugs for the treatment of acute coronary syndrome
Publication in refereed journal

Times Cited
Web of Science1WOS source URL (as at 04/12/2020) Click here for the latest count
Altmetrics Information

Other information
AbstractIntroduction: Ischemic heart disease is the most common cause of death worldwide. Despite improvements in interventional and pharmacological therapy for acute coronary syndrome (ACS), the risk of recurrent myocardial ischemia and mortality early after ACS remains high. Our improved understanding of the increasing role of inflammation in the pathogenesis of ACS and its relationship to atherosclerotic plaque rupture and thrombosis has led to the development of more potent anti-thrombotic and novel anti-inflammatory therapies for the treatment of ACS.Areas covered: In this review, the authors explore: the developing pharmacotherapy in the field of cardiology for ACS; antiplatelet agents (both further development of classical modalities together with pioneering agents); evolving use of anticoagulation in its treatment, and exploration in the use of novel anti-inflammatories and biological agents.Expert opinion: Data from trials involving the use of immunological and cellular-based treatments show promising results and herald further possible reduction in infarct burden in ACS alongside the possibility of recovery in cardiac function following infarction.
All Author(s) ListO'Connor CT, Kiernan TJ, Yan BP
Journal nameExpert Opinion on Investigational Drugs
Volume Number24
Issue Number12
Pages1557 - 1570
LanguagesEnglish-United Kingdom
Keywordsacute coronary syndrome; anticoagulation therapy; antiinflammatory therapy; antiplatelet therapy
Web of Science Subject CategoriesPharmacology & Pharmacy

Last updated on 2020-05-12 at 00:33